A Phase 1/2 Open-label Study Investigating the Safety Tolerability and Efficacy of ASP7517 in subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Relapsed/refractory Acute Myeloid Leukemia (aml) And Relapsed/refractory Higher Risk Myelodysplastic Syndrome (mds)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Subject diagnosed with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS). 2) Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of = 2. 3) Subjects with AML must have peripheral blood absolute blast count of < 20,000/µL at C1D1.

You may not be eligible for this study if the following are true:

  • 1) Subject was diagnosed with acute promyelocytic leukemia. 2) Subject has breakpoint cluster region-Abelson-positive leukemia (BCR-ABL). 3) Subject has persistent non-hematological toxicities of = grade 2 (National Cancer Institute’s Common Terminology Criteria for Adverse Events [NCI-CTCAE]. 4) Subject has clinically active nervous system leukemia, per the investigator’s judgment.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.